论文部分内容阅读
目的观察奥沙利铂联合替吉奥治疗进展期胃癌的疗效。方法选择2014年5月—2016年5月诊治的老年进展期胃癌患者102例,随机分为对照组与观察组,各51例。前者予奥沙利铂与替加氟联合治疗,后者予奥沙利铂与替吉奥联合治疗。观察两组生活质量、临床疗效及不良反应情况。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异具统计学意义。结果观察组社会、角色及躯体功能评分[(59.70±15.68)、(70.11±15.59)分、(65.23±8.69)分]比对照组[(53.48±14.79)、(61.03±17.28)、(53.21±8.97)分]高(均P<0.05);观察组临床获益率(clinical benefit rate,CBR)、疾病控制率(disease control rate,DCR)(90.20%、74.51%)比对照组(70.59%、35.29%)高(均P<0.05);两组不良反应比较差异无统计学意义(均P>0.05)。结论奥沙利铂联合替吉奥治疗进展期胃癌疗效好,可显著改善患者的生活质量。
Objective To observe the curative effect of oxaliplatin combined with tirolidil on advanced gastric cancer. Methods 102 elderly patients with advanced gastric cancer who were diagnosed and treated from May 2014 to May 2016 were randomly divided into control group and observation group, with 51 cases in each group. The former to oxaliplatin and tegafur combination therapy, the latter to oxaliplatin and for treatment of Gioia. The quality of life, clinical efficacy and adverse reactions of the two groups were observed. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results Compared with the control group [(53.48 ± 14.79), (61.03 ± 17.28) and (53.21 ±)), the scores of social, role and physical function in the observation group were significantly higher than those in the control group [(59.70 ± 15.68), (70.11 ± 15.59), (65.23 ± 8.69) (P <0.05). The clinical benefit rate (CBR) and disease control rate (DCR) in the observation group (90.20%, 74.51%) were significantly higher than those in the control group (70.59% 35.29%) (all P <0.05). There was no significant difference in adverse reactions between the two groups (all P> 0.05). Conclusion The combination of oxaliplatin and tioguanil is effective in treating advanced gastric cancer and can significantly improve the quality of life of patients.